ABSTRACT
In Ethiopia, dengue virus (DENV) infections have been reported in several regions, however, little is known about the circulating genetic diversity. Here, we conducted clinical surveillance for DENV during the 2023 nationwide outbreak and sequenced DENV whole genomes for the first time in Ethiopia. We enrolled patients at three sentinel hospital sites. Using RT-PCR, we screened serum samples for three arboviruses followed by serotyping and sequencing for DENV-positive samples (10.4% of samples). We detected two DENV serotypes (DENV1 and DENV3). Phylogenetic analysis identified one transmission cluster of DENV1 (genotype III major lineage A), and two clusters of DENV3 (genotype III major lineage B). The first showed close evolutionary relationship to the 2023 Italian outbreak and the second cluster to Indian isolates. Co-circulation of DENV1 and DENV3 in some regions of Ethiopia highlights the potential for severe dengue. Intensified surveillance and coordinated public health response are needed to address the threat of severe dengue outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ethiopian Public Health Institute and Addis Ababa University, KRISP and CERI
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study obtained ethical approval from Addis Ababa University (Ref. no. CNCSDO/175/15/2023), and Institutional Review Boards (IRBs) of the Ethiopian Public Health Institute (EPHI-IRB-536-2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability Statement
All sequences used for this manuscript are publicly available on the GISAID EpiArbo database, subject to its terms and conditions (https://www.gisaid.org/), GISAID identifier: EPI_ISL_19229161 - EPI_ISL_19229193.
Abbreviations
- BAM
- Binary Alignment Map
- CDC
- Center for Diseases Control and prevention
- CERI
- Center for Emerging and Re-emerging Infectious diseases
- CHIKV
- Chikungunya virus
- CLIMADE
- Climate Amplified Diseases and Epidemics
- COVID-19
- Corona Virus Diseases-19
- DENV
- Dengue virus
- EPHI
- Ethiopian Public Health Institute
- GISAID
- Global initiative on sharing all influenza data
- HPD
- Highest Posterior Density
- IATA
- International Air Transport Association
- IRB
- Institutional Review Board
- KRISP
- KwaZulu-Natal Research Innovation and Sequencing Platform
- MCC
- Maximum Clade Credibility
- NCBI
- National Centre for Biotechnology Information
- RT-PCR
- Reverse transcription polymerase chain reaction
- TMRCA
- The Most Common Recent Ancestor
- ZIKV
- Zika virus
